secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2026-05-12T12:00:07+00:00
Accession:  0001193125-26-218224
Event type: earnings
Sentiment:  neutral
Materiality: 0.45
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Q1 net loss $15.7M; cash $118.8M; Phase 3 topline data expected Q3 2026
-----------------------------------------------------------------------------

- Net loss of $15.7M for Q1 2026 vs $10.4M in Q1 2025; R&D expense rose to $11.5M from $5.7M.
- Cash and equivalents $118.8M as of March 31, 2026; expected to fund operations through at least Q1 2028.
- Phase 3 LEVEL study fully randomized (>230 patients); topline data anticipated in Q3 2026.
- Appointed Thomas Staab as CFO, Timothy Healey as CCO, and So-Young Kim as EVP Clinical Development.
- Phase 3 LEVEL-2 trial ongoing; enrollment completion expected by end of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000119312526218224/0001193125-26-218224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000119312526218224/d91737d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer